Therapy News and Research

RSS

Article spotlights new way to find adverse drug reactions within electronic health records

The time may be fast approaching for researchers to take better advantage of the vast amount of valuable patient information available from U.S. electronic health records. Lian Duan, an NJIT computer scientist with an expertise in data mining, has done just that with the recent publication of "Adverse Drug Effect Detection," IEEE Journal of Biomedical and Health Informatics (March, 2013).

15 May 2013

Prostate cancer patients need to be aware of the effects of androgen deprivation therapy

Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment.

15 May 2013

Study shows dual-chamber ICDs are associated with higher risk of device-related complications

Even though patients receiving an implantable cardioverter-defibrillator for primary prevention often receive a dual-chamber ICD, an analysis that included more than 32,000 patients receiving an ICD without indications for pacing finds that the use of a dual-chamber device compared with a single-chamber device was associated with a higher risk of device-related complications and similar 1-year mortality and hospitalization outcomes, according to a study in the May 15 issue of JAMA.

15 May 2013

LDL cholesterol blood level declines found to have abruptly ended in 2008

Decades of declines in LDL cholesterol blood levels, a key marker of death risk from heart disease, abruptly ended in 2008, and may have stalled since, according to a multi-year, national study published in PLOS ONE.

From Quest Diagnostics 14 May 2013

Researchers show how cells are driven mainly by water power

Water gives life. Researchers at Linköping University in Sweden now show how the cells in our bodies are driven mainly by water power - a discovery that in the long run opens the way for a new strategy in cancer therapy.

14 May 2013

FDA OKs TWi Pharmaceuticals' tentative ANDA for Guanfacine Hydrochloride Extended Release Tablets

TWi Pharmaceuticals, Inc. today announced that it has received tentative approval for its Abbreviated New Drug Application for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg from the United States Food and Drug Administration.

14 May 2013

Renaissance in drug development for rare diseases

Once famously described as "orphan diseases, too small to be noticed, too small to be funded" in the Hollywood drama Lorenzo's Oil, rare diseases are getting unprecedented attention today among drug manufacturers, who are ramping up research efforts and marketing new medicines that promise fuller lives for children and other patients with these heartbreaking conditions.

14 May 2013

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein.

14 May 2013

Research findings may pave way to new treatment for Alzheimer's disease in humans

A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment.

14 May 2013

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).

14 May 2013

Tel Aviv University researchers invent a method for repairing damaged peripheral nerves

Some parts of the body, like the liver, can regenerate themselves after damage. But others, such as our nervous system, are considered either irreparable or slow to recover, leaving thousands with a lifetime of pain, limited mobility, or even paralysis.

14 May 2013

FDA grants priority review for Janssen's simeprevir

Medivir AB today announces that the U.S. Food and Drug Administration has granted Priority Review to the New Drug Application by Janssen for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.

14 May 2013

Sorin Group receives FDA approval for SMARTVIEW remote monitoring solution

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, today announced it received FDA approval for and is beginning the U.S. launch of the SMARTVIEW remote monitoring solution for patients with implanted cardiac rhythm management devices.

13 May 2013

New NIH funding to help researchers explore promising new approaches to cure stroke

Dr. Gregory Bix, Paul G. Blazer J. Professor of Stroke Research in the University of Kentucky Sanders-Brown Center on Aging and the UK departments of Anatomy and Neurobiology and Neurology, has received funding of $224,416 from the National Institutes of Health, to further study of stroke recovery.

13 May 2013

Exposure to Agent Orange may increase risk of developing lethal forms of prostate cancer

A new analysis has found a link between exposure to Agent Orange and lethal forms of prostate cancer among US Veterans. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that Agent Orange exposure history should be incorporated into prostate screening decisions for Veterans.

13 May 2013

New challenges to military medicine

Better body armor and rapid aeromedical evacuations enable American service members to survive blasts that would have proved fatal in Vietnam or even the first Gulf War, but they pose new challenges to military medicine - how to deal with the excruciating pain of injuries, especially severe burns from IED blasts that body armor can't protect.

13 May 2013

TYRX's AIGISRx Antibacterial Envelope reduces CIED infection rates by more than 90%

Use of TYRX, Inc.'s AIGISRx- Antibacterial Envelope reduced major infection rates by more than 90% in patients undergoing Cardiovascular Implantable Electronic Device replacement procedures compared to similar high-risk cohorts, according to the CITADEL & CENTURION clinical study results presented on Saturday at the Late Breaking Clinical Trials session at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions.

13 May 2013

Therapy News and Research

Article spotlights new way to find adverse drug reactions within electronic health records

Prostate cancer patients need to be aware of the effects of androgen deprivation therapy

Study shows dual-chamber ICDs are associated with higher risk of device-related complications

LDL cholesterol blood level declines found to have abruptly ended in 2008

Researchers show how cells are driven mainly by water power

FDA OKs TWi Pharmaceuticals' tentative ANDA for Guanfacine Hydrochloride Extended Release Tablets

Renaissance in drug development for rare diseases

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Research findings may pave way to new treatment for Alzheimer's disease in humans

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

Tel Aviv University researchers invent a method for repairing damaged peripheral nerves

FDA grants priority review for Janssen's simeprevir

Sorin Group receives FDA approval for SMARTVIEW remote monitoring solution

New NIH funding to help researchers explore promising new approaches to cure stroke

Exposure to Agent Orange may increase risk of developing lethal forms of prostate cancer

New challenges to military medicine

TYRX's AIGISRx Antibacterial Envelope reduces CIED infection rates by more than 90%

Research: Patients with chronic pain should be evaluated for anxiety disorders

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

Researchers identify clue to explain the reversible memory loss caused by statins

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News